LEADER 01099cam0-2200337---450- 001 990004868200403321 005 20110126164909.0 035 $a000486820 035 $aFED01000486820 035 $a(Aleph)000486820FED01 035 $a000486820 100 $a19990604g19611966km-y0itay50------ba 101 0 $aeng 102 $aGB 105 $ay-------001by 200 1 $aKing Henry IV$f[William Shakespeare]$gedited by A. R. Humphreys 210 $aLondon$cMethuen$aCambridge (Mass.)$cHarvard University press$d1960-1966 215 $a2 v.$d23 cm 225 1 $a<>Arden edition of the works of William Shakespeare 327 1 $a1.: The first part. - 1960$a2.: The second part. - 1966 676 $a822.33 700 1$aShakespeare,$bWilliam$f<1564-1616>$0132200 702 1$aHumphreys,$bArthur Raleigh$f<1911- > 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990004868200403321 952 $a822.33 SHAK W1(2;1)$bIst.f.m.10053$fFLFBC 952 $a822.33 SHAK W1(2;2)$bIst.f.m.14306$fFLFBC 959 $aFLFBC 996 $aKing Henry IV$9157223 997 $aUNINA LEADER 03325nam 22005295 450 001 9910483196003321 005 20200705023456.0 010 $a3-540-89891-3 024 7 $a10.1007/978-3-540-89891-7 035 $a(CKB)2670000000062028 035 $a(DE-He213)978-3-540-89891-7 035 $a(SSID)ssj0000476077 035 $a(PQKBManifestationID)11913333 035 $a(PQKBTitleCode)TC0000476077 035 $a(PQKBWorkID)10479325 035 $a(PQKB)10368846 035 $a(MiAaPQ)EBC3066280 035 $a(PPN)149902336 035 $a(EXLCZ)992670000000062028 100 $a20101224d2011 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aDrug Discovery and Evaluation: Methods in Clinical Pharmacology$b[electronic resource] /$fedited by H.Gerhard Vogel, Jochen Maas, Alexander Gebauer 205 $a1st ed. 2011. 210 1$aBerlin, Heidelberg :$cSpringer Berlin Heidelberg :$cImprint: Springer,$d2011. 215 $a1 online resource (XII, 564p. 138 illus.. eReference.) 300 $a"With 153 figures and 95 tables." 311 $a3-540-89892-1 311 $a3-540-89890-5 320 $aIncludes bibliographical references and index. 327 $asection A. Introduction -- section B. Clinical pharmacokinetics -- section C. Human studies in clinical pharmacology -- section D. Regulations. 330 $aDrug Discovery and Evaluation has become a more and more difficult, expensive and time-consuming process. The effect of a new compound has to be detected by in vitro and in vivo methods of pharmacology. The activity spectrum and the potency compared to existing drugs have to be determined. As these processes can be divided up stepwise we have designed a book series "Drug Discovery and Evaluation" in the form of a recommendation document. The methods to detect drug targets are described in the first volume of this series "Pharmacological Assays" comprising classical methods as well as new technologies. Before going to man, the most suitable compound has to be selected by pharmacokinetic studies and experiments in toxicology. These preclinical methods are described in the second volume ?Safety and Pharmacokinetic Assays". Only then are first studies in human beings allowed. Special rules are established for Phase I studies. Clinical pharmacokinetics are performed in parallel with human studies on tolerability and therapeutic effects. Special studies according to various populations and different therapeutic indications are necessary. These items are covered in the third volume: ?Methods in Clinical Pharmacology". 606 $aPharmacology 606 $aPharmacology/Toxicology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21007 615 0$aPharmacology. 615 14$aPharmacology/Toxicology. 676 $a615 702 $aVogel$b H.Gerhard$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aMaas$b Jochen$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aGebauer$b Alexander$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910483196003321 996 $aDrug Discovery and Evaluation: Methods in Clinical Pharmacology$92513355 997 $aUNINA